Tim Schlidt

Tim Schlidt is a co-founder and partner at Palo Santo since May 2020, with extensive experience in healthcare and investment. Tim serves on the board of directors for Ksana Health and has board observer roles at Gilgamesh Pharmaceuticals, Kanna Health, and Bexson Biomedical. Tim has also been an advisor to Tactogen since December 2021. Previously, Tim was a board member at Reset Pharmaceuticals until February 2023. Prior to these roles, Tim worked as a private equity associate at Madison Dearborn Partners, LLC, and as an investment banking analyst at Greenhill & Co., focusing on life sciences and healthcare services. Tim began a career in investment banking with a summer analyst position at J.P. Morgan, specializing in healthcare coverage. Tim holds a Bachelor of Business Administration in Finance, Investment & Banking from the University of Wisconsin-Madison.